Re­gen­eron, Sanofi, get ready to duke it out with Pfiz­er over a megablock­buster eczema mar­ket

Some­time over the next few days or weeks, the FDA will like­ly hand Re­gen­eron and Sanofi an ap­proval for Dupix­ent (dupilum­ab), their ground­break­ing IL-4/IL-13 in­hibitor for eczema which a num­ber of an­a­lysts have pro­ject­ed will go on to grab $4 bil­lion-plus a year in an­nu­al sales. And they’ll hit the mar­ket with some stel­lar new 16- and 52-week da­ta from an­oth­er Phase III study as they go up against Pfiz­er’s new­ly ap­proved Eu­crisa (crisabo­role, tar­get­ing PDE4).

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.